Merck upbeat on new data for MK-0524
Merck is sounding decidedly upbeat about the recent data on MK-0524, an experimental therapy for reducing flushing in patients with dyslipidemia. Flushing is an uncomfortable and common side effect associated with niacin and one of the primary reasons why patients stop taking the therapy. Dyslipidemia is a condition that disrupts the quantity of lipids in the blood. Merck is currently in Phase III with MK-0524A, a combination of MK-0524 and extended release niacin.
- here's the AFX report on the trial data
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
